Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lethagen

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|December 18, 1987
Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibilityS Lethagen, A S Harris, E Sjörin, et al.
Lakartidningen|February 24, 2001
[Use the entire "analysis package" when investigating patients with venous thrombosis! Don't forget the relatives...]K E Persson, A Hillarp, S Lethagen, et al.
Vox Sanguinis|December 20, 2005
Factors influencing factor VIII activity in frozen plasmaA-M Swärd-Nilsson, P-O Persson, U Johnson, et al.
Thrombosis and Haemostasis|July 31, 1998
Revised classification and treatment of von Willebrand diseaseS Lethagen, K Frick, C Isaksson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 12, 2016
Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFcE Berntorp, C Negrier, P Gozzi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Economic evaluation: what are we looking for and how do we get there?K Steen Carlsson, S Höjgård, S Lethagen, et al.
Thrombosis and Haemostasis|November 15, 1993
Biochemical and in vivo properties of high purity factor IX concentratesE Berntorp, S Björkman, M Carlsson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2003
Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiencyE Berntorp, E Piitulainen, S Lethagen, et al.
Journal of Internal Medicine|August 11, 1998
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulationJ Astermark, O Björgell, E Lindén, et al.
Journal of Thrombosis and Haemostasis : JTH|April 19, 2007
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgeryS Lethagen, P A Kyrle, G Castaman, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|December 18, 1987
Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibilityS Lethagen, A S Harris, E Sjörin, et al.
Lakartidningen|February 24, 2001
[Use the entire "analysis package" when investigating patients with venous thrombosis! Don't forget the relatives...]K E Persson, A Hillarp, S Lethagen, et al.
Vox Sanguinis|December 20, 2005
Factors influencing factor VIII activity in frozen plasmaA-M Swärd-Nilsson, P-O Persson, U Johnson, et al.
Thrombosis and Haemostasis|July 31, 1998
Revised classification and treatment of von Willebrand diseaseS Lethagen, K Frick, C Isaksson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 12, 2016
Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFcE Berntorp, C Negrier, P Gozzi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Economic evaluation: what are we looking for and how do we get there?K Steen Carlsson, S Höjgård, S Lethagen, et al.
Thrombosis and Haemostasis|November 15, 1993
Biochemical and in vivo properties of high purity factor IX concentratesE Berntorp, S Björkman, M Carlsson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2003
Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiencyE Berntorp, E Piitulainen, S Lethagen, et al.
Journal of Internal Medicine|August 11, 1998
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulationJ Astermark, O Björgell, E Lindén, et al.
Journal of Thrombosis and Haemostasis : JTH|April 19, 2007
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgeryS Lethagen, P A Kyrle, G Castaman, et al.
Pageof 10